Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2026)
Anaptysbio's (ANAB) quarterly Total Non-Current Liabilities came in at $65.9 million in Q1 2026, down 28.07% YoY from $91.7 million in Q1 2025, and down 24.95% on a QoQ basis from $87.9 million in Q4 2025.
Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Total Non-Current Liabilities data on file, last reported at $65.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 28.07% year-over-year to $65.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.9 million (down 28.07% YoY) and the FY2025 annual result came in at $87.9 million, down 32.62% from the prior year.
- Total Non-Current Liabilities fell to $65.9 million in Q1 2026, from $87.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $583.5 million in Q3 2022 to a low of $3.9 million in Q2 2025.
- A 5-year average of $180.9 million and a median of $141.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 4.16% in 2025, down 94.05% in 2025.
- Tracing ANAB's Total Non-Current Liabilities over 5 years: stood at $306.0 million in 2022, then slumped by 53.73% to $141.6 million in 2023, then decreased by 7.89% to $130.4 million in 2024, then sank by 32.62% to $87.9 million in 2025, then fell by 24.95% to $65.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $65.9 million (Q1 2026), $87.9 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 65.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.94 Mn |
| Dec 31, 2025 | 87.87 Mn |
| Sep 30, 2025 | 21.25 Mn |
| Jun 30, 2025 | 3.89 Mn |
| Mar 31, 2025 | 91.67 Mn |
| Dec 31, 2024 | 130.41 Mn |
| Sep 30, 2024 | 142.85 Mn |
| Jun 30, 2024 | 65.40 Mn |
| Mar 31, 2024 | 95.65 Mn |
| Dec 31, 2023 | 141.58 Mn |
| Sep 30, 2023 | 176.05 Mn |
| Jun 30, 2023 | 207.03 Mn |
| Mar 31, 2023 | 244.28 Mn |
| Dec 31, 2022 | 305.97 Mn |
| Sep 30, 2022 | 583.50 Mn |
| Jun 30, 2022 | 342.83 Mn |
| Mar 31, 2022 | 369.59 Mn |
| Dec 31, 2021 | 391.98 Mn |
| Dec 31, 2020 | 416.55 Mn |
| Sep 30, 2020 | 384.72 Mn |